Chou Alexander J, Gorlick Richard
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85. doi: 10.1586/14737140.6.7.1075.
For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival. In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
对于骨肉瘤患者，化疗的应用已使生存率从20世纪60年代单纯手术切除时的11%提高到20世纪80年代中期的70%。然而，尽管抗癌治疗取得了进展，但生存率此后一直停滞不前。阐明化疗耐药机制并实施克服化疗耐药的策略可能对提高生存率至关重要。在本综述中，重点是目前对骨肉瘤治疗中最常用药物的耐药机制的理解以及用于克服化疗耐药的方法。
